AroCell AB (publ) announced today that the patent no 105980407 and titled “Monoclonal anti-TK1 antibodies” is granted by China National Intellectual Property Administration (CNIPA).
The patent relates to AroCell’s proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. The antibodies approved in the patent is used in the AroCell TK 210 ELISA kit.
“We are delighted that this patent has been granted by China National Intellectual Property Administration. This reinforces our patent position in China and increases AroCell’s attractiveness as a business partner in Asia. We will continue to develop our portfolio of proprietary assets to further expand our business opportunities and to support our product AroCell TK 210 ELISA.” says Michael Brobjer, CEO AroCell.